AKT inhibitor AZD5363 well tolerated, yielded partial response in patients with advanced solid tumors
The investigational drug AZD5363, which has shown activity in preclinical studies, was well tolerated in humans, and two patients with advanced solid tumors showed partial response, according to data presented at the AACR ...
Cancer
Apr 08, 2013 |
5 / 5 (1) |
0
BRAF mutation less common among patients with melanoma in Ireland
The BRAF mutation believed to drive disease in about half of patients with melanoma was found to occur at a significantly lower frequency in patients with melanoma in Ireland, according to data presented at the AACR Annual ...
Cancer
Apr 08, 2013 |
not rated yet |
0
Immunotherapy showed promising antileukemia activity in pediatric patients
Researchers using patients' own immune cells in an immunotherapy approach called "anti-CD19 chimeric antigen receptor (CAR) T-cell therapy," achieved responses in children whose acute lymphocytic leukemia (ALL) had returned ...
Cancer
Apr 07, 2013 |
5 / 5 (1) |
0
Biomarker analysis identified women most likely to benefit from T-DM1
For women with metastatic, HER2-positive breast cancer, the amount of HER2 on their tumor might determine how much they benefit from a drug called trastuzumab emtansine (T-DM1), according to data from a subanalysis of the ...
Cancer
Apr 07, 2013 |
not rated yet |
0
Some patients with incurable tumors and BRCA mutations respond to new two-drug combination
A novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the ...
Cancer
Apr 07, 2013 |
5 / 5 (1) |
0
Low levels of serum bilirubin spell higher lung cancer risk for male smokers
Elevated levels of bilirubin in the blood get attention in the clinic because they often indicate that something has gone wrong with the liver. Now researchers have found that male smokers with low levels of the yellow-tinged ...
Cancer
Apr 07, 2013 |
4 / 5 (1) |
0
|
Two-step ovarian cancer immunotherapy made from patients' own tumor shows promise
As many as three quarters of advanced ovarian cancer patients appeared to respond to a new two-step immunotherapy approach—including one patient who achieved complete remission—according research from the Perelman School ...
Cancer
Apr 06, 2013 |
5 / 5 (1) |
0
Smoking worsens outcomes with advanced colon cancer
(HealthDay)—Smoking is tied to significantly shorter disease-free survival (DFS) and time to recurrence (TTR) in patients undergoing treatment for stage III colon cancer, according to a study published ...
Cancer
Apr 06, 2013 |
5 / 5 (1) |
2
Individualized genomic testing allows for tailored cancer treatment, new drug research
Just like a massive iceberg jutting out of the ocean, many of cancer's genetic underpinnings remain hidden under the surface, impossible to predict or map from above. The foreboding shadows and shapes that appear on CT scans ...
Cancer
Apr 05, 2013 |
not rated yet |
0
Study finds virtual colonoscopy is used appropriately, may expand screening to more patients
In 2009, the Centers for Medicare and Medicaid Services (CMS) halted reimbursement for so-called "virtual colonoscopy" for routine colon-cancer screening in asymptomatic patients, in part due to concerns over how this procedure, ...
Cancer
Apr 05, 2013 |
not rated yet |
0
"Never events" rare after bladder cancer surgery
(HealthDay)—"Never events", ten hospital-acquired conditions deemed by the Centers for Medicare and Medicaid Services as being reasonably preventable, are rare in patients with bladder cancer who have undergone ...
Surgery
Apr 05, 2013 |
not rated yet |
0
Cancer patients may be unintended victims of budget cuts
(HealthDay)—Thousands of Medicare cancer patients are being denied treatment at clinics nationwide because of federal budget cuts related to the so-called sequester, according to a published report.
Health
Apr 04, 2013 |
5 / 5 (1) |
0
On-and-off approach to prostate cancer treatment may compromise survival
Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.
Cancer
Apr 03, 2013 |
not rated yet |
0
|
Advances in molecular testing offer new hope for lung cancer patients
The emergence of molecular diagnostic testing in lung cancer offers new hope for patients battling the number one cancer killer in the United States and abroad. Now, for the first time after a decade of biomarker testing ...
Cancer
Apr 03, 2013 |
not rated yet |
0
Researchers say one specific microrna promotes tumor growth and cancer spread
Researchers at Moffitt Cancer Center have determined that the overexpression of microRNA-155 (miR-155), a short, single strand of ribonucleic acid encoded by the miR-155 host gene, promotes the growth of blood vessels in ...
Cancer
Apr 03, 2013 |
5 / 5 (1) |
0
|
